Telaglenastat
Glutaminase inhibitor combined with nivolumab; ENTRATA trial in RCC. Glutamine deprivation + checkpoint — metabolic + immune combo
Description
Scientific Overview: Glutaminase inhibitor combined with nivolumab; ENTRATA trial in RCC. Glutamine deprivation + checkpoint — metabolic + immune combo
Mechanism of Action: GLS1 + checkpoint combination
Purity: ≥99% | Molecular Formula: N/A
For Research Use Only. Not intended for diagnostic, therapeutic, or clinical applications.
Additional information
| Effect | GLS1 + checkpoint combination |
|---|---|
| Purity | ≥99% |
| Molecular Formula | |
| CAS Number |
